Block listing Interim Review

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

Name of applicant:	Hikma Pharmaceuticals PLC
Name of scheme:	Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")
Period of return	From: 1 April 2021	To:	30 September 2021
Balance of unallotted securities under scheme(s) from previous return:	SOP: 792,700 Ordinary Shares of 10 pence
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	SOP: 0 Ordinary Shares of 10 pence
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	SOP: 0 Ordinary Shares of 10 pence
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	SOP: 792,700 Ordinary Shares of 10 pence

Name of contact:	Peter Speirs
Telephone number of contact:	0207 399 2772

Name of applicant:	Hikma Pharmaceuticals PLC
Name of scheme:	Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")
Period of return	From: 1 April 2021	To:	30 September 2021
Balance of unallotted securities under scheme(s) from previous return:	LTIP: 57,502 Ordinary Shares of 10 pence
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	LTIP: 0 Ordinary Shares of 10 pence
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	LTIP: 0 Ordinary Shares of 10 pence
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	LTIP: 57,502 Ordinary Shares of 10 pence

Name of contact:	Peter Speirs
Telephone number of contact:	0207 399 2772

Name of applicant:	Hikma Pharmaceuticals PLC
Name of scheme:	Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009MIP")
Period of return	From: 1 April 2021	To:	30 September 2021
Balance of unallotted securities under scheme(s) from previous return:	2009 MIP: 136,182 Ordinary Shares of 10 pence
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	2009 MIP: 0 Ordinary Shares of 10 pence
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	2009 MIP: 136,182 Ordinary Shares of 10 pence
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	2009 MIP: 0 Ordinary Shares of 10 pence

Companies

UK 100

Latest directors dealings